Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer.
MONALEESA-3 study in HR+/HER2- advanced breast cancer
